These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18257512)

  • 1. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
    Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
    J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative assessment of hERG liability as a function of lipophilicity.
    Waring MJ; Johnstone C
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1759-64. PubMed ID: 17239590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites.
    Shamovsky I; de Graaf C; Alderin L; Bengtsson M; Bladh H; Börjesson L; Connolly S; Dyke HJ; van den Heuvel M; Johansson H; Josefsson BG; Kristoffersson A; Linnanen T; Lisius A; Männikkö R; Nordén B; Price S; Ripa L; Rognan D; Rosendahl A; Skrinjar M; Urbahns K
    J Med Chem; 2009 Dec; 52(23):7706-23. PubMed ID: 19954248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive in silico modeling for hERG channel blockers.
    Aronov AM
    Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning out of hERG.
    Aronov AM
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiscale simulation system for the prediction of drug-induced cardiotoxicity.
    Obiol-Pardo C; Gomis-Tena J; Sanz F; Saiz J; Pastor M
    J Chem Inf Model; 2011 Feb; 51(2):483-92. PubMed ID: 21250697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A QSAR model of HERG binding using a large, diverse, and internally consistent training set.
    Seierstad M; Agrafiotis DK
    Chem Biol Drug Des; 2006 Apr; 67(4):284-96. PubMed ID: 16629826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
    Du-Cuny L; Chen L; Zhang S
    J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
    Moorthy NS; Ramos MJ; Fernandes PA
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand structural aspects of hERG channel blockade.
    Aronov AM
    Curr Top Med Chem; 2008; 8(13):1113-27. PubMed ID: 18782007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
    Diller DJ; Hobbs DW
    J Comput Aided Mol Des; 2007 Jul; 21(7):379-93. PubMed ID: 17549583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.